AMCG Wins Top Prize at 'Seoul - K-OTC Joint Scale-Up IR'

☞ Go to article

Seo Yong-seong, CEO of AMCG (first on the left), poses for a commemorative photo after receiving the Grand Prize at the ‘Scale-Up IR Event’.

AMCG, a startup developing next-generation heart disease diagnostic solutions using quantum sensors and artificial intelligence (AI) technology, announced on the 19th that it won the top prize at the ‘Scale-up IR Event’ jointly hosted by the Seoul Metropolitan Government and the Korea Financial Investment Association (K-OTC).

This joint Scale-Up IR event was organized to support promising companies with high growth potential in securing funding. It was conducted before a panel of 10 judges comprising securities firms, asset managers, and venture capital (VC) firms. The judges conducted a comprehensive evaluation across four categories: organizational capability, market potential, technological capability, and business viability. AMCG received the highest score and was awarded the Grand Prize. 

AMCG possesses core technology in its Magnetocardiograph (MCG) scanning system. This system features the world's largest configuration of 96 channels using world-leading superconducting quantum interference device (SQUID) sensors.

It is particularly recognized for implementing medical devices optimized for the early diagnosis of ischemic heart disease by effectively eliminating environmental magnetic noise using AI technology and advancing diagnostic algorithms.

The greatest advantage of the cardiac electrocardiogram scan is its ability to perform measurements completely non-invasively, without contrast agents or radiation exposure. This innovative diagnostic method ana lyzes the heart's electrophysiological data to determine the presence of heart disease, significantly reducing patient burden compared to existing examination methods.

Related products are now being launched in the largest markets, the United States and China, and numerous clinical trials are underway. Consequently, market interest is growing as it emerges as next-generation cardiac disease diagnostic equipment.

Seo Yong-seong, CEO of AMCG, stated, “Leveraging Seoul Metropolitan Government's institutio nal investor network and investment attraction support will be a crucial opportunity to secure tangible growth prospects,” adding, “We will continue to collaborate with diverse partners and strive to remain a company that persistently challenges itself in both domestic and international markets.”

Meanwhile, through this award, AMCG anticipates securing additional investment attraction opportunities by utilizing the investment ecosystem networks of Seoul Metropolitan Government and K-OTC.

[Financial News Reporter Jung Myeong-jin]